Recent Quotes (30 days)

You have no recent quotes
chg | %

Arrowhead Pharmaceuticals Inc  

(Public, NASDAQ:ARWR)   Watch this stock  
Find more results forARWR
3.99
+0.10 (2.70%)
Real-time:   11:16am GMT-4
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.79 - 4.05
52 week 1.20 - 6.86
Open 3.85
Vol / Avg. 306,656.00/1.50M
Mkt cap 298.71M
P/E     -
Div/yield     -
EPS -0.67
Shares 74.77M
Beta 1.94
Inst. own 21%
Dec 12, 2017
Q4 2017 Arrowhead Pharmaceuticals Inc Earnings Release (Estimated) - 4:00pm GMT-5 - Add to calendar
Oct 10, 2017
Arrowhead Pharmaceuticals Inc at Chardan Inaugural Gene Therapy Conference
Sep 25, 2017
Arrowhead Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 14, 2017
Arrowhead Pharmaceuticals Inc Research & Development Day - Webcast
Aug 3, 2017
Q3 2017 Arrowhead Pharmaceuticals Inc Earnings Call - Webcast
Aug 3, 2017
Q3 2017 Arrowhead Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -59.08% -51615.61%
Operating margin -61.16% -51628.07%
EBITD margin - -48273.78%
Return on average assets -18.30% -62.76%
Return on average equity -24.07% -79.44%
Employees 113 -
CDP Score - -

Address

225 S Lake Ave Ste 1050
PASADENA, CA 91101-4820
United States - Map
+1-626-3043400 (Phone)
+1-626-3043401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Officers and directors

Douglass B. Given M.D., Ph.D. Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Christopher Richard Anzalone Ph.D. President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Kenneth Allen Myszkowski Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Bruce D. Given M.D. Chief Operating Officer
Age: 62
Bio & Compensation  - Reuters
Patrick O'Brien General Counsel
Age: 53
Bio & Compensation  - Reuters
Michael S. Perry Ph.D. Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Mauro Ferrari Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Edward W. Frykman Independent Director
Age: 80
Bio & Compensation  - Reuters